# Caris Life Sciences (CAI) — Earnings

CAI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cai/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.00 |
| EPS estimate | $0.01 |
| EPS surprise | −100.00% |
| Revenue surprise | +10.75% |
| Revenue | $263.7M |
| Revenue estimate | $238.1M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/2019410/000201941026000055/cai-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/db5f143f-79a7-8895-505a-9180a36c8daf.html) |

Caris Life Sciences reported Q2 2026 results on August 5, 2026. Earnings per share were $0.00, against a $0.01 estimate, which the source records as a 100% miss. Revenue was $263.7 million against a $238.1 million consensus, a beat of 10.75%. Compared with Q2 2025, revenue rose about 45% from $181.4 million. EPS improved from a loss of $7.97 per share a year earlier to break-even.

The record is short, with only five quarters in the table, starting from Q2 2025. That first quarter was a loss of $7.97 per share, far below the estimated loss of $0.22. EPS was then $0.08 in Q3 2025 and $0.28 in Q4 2025, before two quarters at $0.00. Revenue grew in most quarters, from $181.4 million to a high of $292.9 million in Q4 2025, and Q2 2026 revenue rose about 22% from Q1 2026. Caris beat the EPS estimate three times and missed twice. No full fiscal year is complete in the table.

The only Q3 report on record came on November 5, 2025, which points to early November 2026 for the next report if that timing holds. It will give the table its first year-over-year comparison for a third quarter.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $0.01 | $0.00 | -100.00% | $238.1M | $263.7M |
| Q1 2026 | May 7, 2026 | −$0.02 | $0.00 | 100.00% | $209.4M | $216.2M |
| Q4 2025 | Feb 26, 2026 | $0.03 | $0.28 | 723.53% | $240.4M | $292.9M |
| Q3 2025 | Nov 5, 2025 | −$0.18 | $0.08 | 145.66% | $174.1M | $216.8M |
| Q2 2025 | Aug 12, 2025 | −$0.22 | −$7.97 | -3550.94% | $138.0M | $181.4M |

## Frequently Asked Questions

### When did Caris Life Sciences (CAI) last report earnings?

Caris Life Sciences last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did CAI beat earnings estimates?

No. Caris Life Sciences reported EPS of $0.00 for Q2 2026 against a $0.01 estimate — a 100.00% miss.

### How much revenue did CAI report last quarter?

Caris Life Sciences reported $263.7M in revenue for Q2 2026, against a consensus estimate of $238.1M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).